Nexaver — predicted protein targets

Predicted protein targets (top 20)

	gene	UniProt	supporting neighbours	confidence
▸	RAF1	P04049	9/20	0.80

▸	KDR	P35968	7/20	0.78

▸	RET	P07949	3/20	0.78

▸	BRAF	P15056	3/20	0.78

▸	PDGFRB	P09619	3/20	0.78

▸	GSK3B	P49841	2/20	0.78

▸	RIPK2	O43353	2/20	0.78

▸	ABCB11	O95342	2/20	0.78

▸	ABL1	P00519	2/20	0.78

▸	HTR1A	P08908	2/20	0.78

▸	ADORA3	P0DMS8	2/20	0.78

▸	KIT	P10721	2/20	0.78

▸	FGFR1	P11362	2/20	0.78

▸	PDGFRA	P16234	2/20	0.78

▸	FLT1	P17948	2/20	0.78

▸	MAOA	P21397	2/20	0.78

▸	EPHA1	P21709	2/20	0.78

▸	TBXA2R	P21731	2/20	0.78

▸	EPHA2	P29317	2/20	0.78

▸	TTK	P33981	2/20	0.78

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
Nexaver SCHEMBL14680554	0.94	RAF1 (0.74)	RAF1KDRRETBRAFPDGFRB
SCHEMBL8167091	0.91	RAF1 (0.78)	RAF1KDRRETBRAFPDGFRB
SCHEMBL10000735	0.90	RAF1 (0.83)	RAF1KDRRETBRAFPDGFRB
SCHEMBL22473669	0.89	RAF1 (0.77)	RAF1KDRRETBRAFPDGFRB
SCHEMBL937568	0.89	RAF1 (1.00)	RAF1KDRRETBRAFPDGFRB
SCHEMBL3407209	0.88	RAF1 (0.80)	RAF1KDRRETBRAFPDGFRB
SCHEMBL29793192	0.88	RAF1 (0.83)	RAF1KDRRETBRAFPDGFRB
SCHEMBL28948534	0.88	RAF1 (0.83)	RAF1KDRRETBRAFPDGFRB
SCHEMBL3408499	0.88	RAF1 (0.83)	RAF1KDRRETBRAFPDGFRB
Sorafenib SCHEMBL15921371	0.88	RAF1 (0.93)	RAF1KDRRETBRAFPDGFRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
EP-4122925-A1	PROTEOLYSIS REGULATOR AND METHOD FOR USING SAME	Medshine Discovery Inc. (CN)	2023-01-25	—	—	EP	disclosed
US-20220193242-A1	IMMUNOPHILIN-DEPENDENT INHIBITORS AND USES THEREOF	THE REGENTS OF THE UNIVERSITY OF CALIFORNIA	2022-06-23	—	—	US	disclosed
US-10787443-B2	RAF-degrading conjugate compounds	ZAMBONI CHEM SOLUTIONS INC. (CA)	2020-09-29	—	—	US	disclosed
WO-2020168172-A1	CONJUGATE COMPOUNDS FOR THE DEGRADATION OF RAF	ZAMBONI CHEM SOLUTIONS INC. (CA)	2020-08-20	—	—	WO	disclosed
US-9809603-B1	Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same	DEUTERX, LLC (US)	2017-11-07	—	—	US	disclosed
US-8445687-B2	Process for the preparation of a RAF kinase inhibitor and intermediates for use in the process	CIPLA LIMITED (IN)	2013-05-21	—	—	US	disclosed
US-20100311980-A1	Process for the Preparation of a RAF Kinase Inhibitor and Intermediates for Use in the Process	CIPLA LIMITED (IN)	2010-12-09	—	—	US	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-20220193242-A1	IMMUNOPHILIN-DEPENDENT INHIBITORS AND USES THEREOF	CD74, CD2BP2, SERPINB1	RAF1 3758/4885KDR 3287/4885RET 4465/4885
US-20100311980-A1	Process for the Preparation of a RAF Kinase Inhibitor and Intermediates for Use in the Process	BRAF, RAF1, ARAF	RAF1 2/4885KDR 272/4885RET 77/4885
US-10787443-B2	RAF-degrading conjugate compounds	BRAF, RAF1, ARAF	RAF1 2/4885KDR 716/4885RET 30/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.